Key points are not available for this paper at this time.
Clotting pathologies in both acute COVID-19 infection and in Long COVID/PASC might benefit from following a regime of continued anticlotting therapy to support the fibrinolytic system function.
Pretorius et al. (Mon,) studied this question.